Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; lactose monohydrate; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-arx is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-arx is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 300 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; sodium starch glycollate; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-str is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-str is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; povidone; stearic acid - indications as at 6 february 2003: main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve: hypoxanthine guanine phosphoriboslytransferase including lesch-nyhan syndrome, glucose 6-phosphatase including glycogen storage disease, phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase. allopurinol-str is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase. allopurinol-str is indicated for the management of recurred mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet - excipient ingredients: stearic acid; lactose monohydrate; sodium starch glycollate type a; maize starch; povidone - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet - excipient ingredients: stearic acid; maize starch; lactose monohydrate; sodium starch glycollate type a; povidone - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome, ? glucose 6-phosphatase including glycogen storage disease, ? phosphoribosylpyrophosphate synthetase, ? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 100 mg - tablet - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; stearic acid; maize starch; povidone - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 300 mg - tablet - excipient ingredients: stearic acid; lactose monohydrate; maize starch; povidone; sodium starch glycollate type a; sunset yellow fcf - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 300 mg - tablet - excipient ingredients: sodium starch glycollate type a; maize starch; povidone; stearic acid; lactose monohydrate; sunset yellow fcf - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - allopurinol, quantity: 300 mg - tablet - excipient ingredients: povidone; sodium starch glycollate type a; maize starch; lactose monohydrate; stearic acid; sunset yellow fcf - main clinical manifestations of urate/uric acid deposition. these are gouty arthritis, skin tophi and/or renal involvement through crystal deposition or stone formation. such clinical manifestations may occur in: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously or after cytotoxic therapy, certain enzyme disorders which lead to overproduction of urate and involve:,? hypoxanthine guanine phosphoribosyltransferase including lesch-nyhan syndrome,,? glucose 6-phosphatase including glycogen storage disease,,? phosphoribosylpyrophosphate synthetase,,? phosphoribosylpyrophosphate amidotransferase.,allopurinol is indicated for the management of 2,8-dihydroxyadenine (2,8-dha) renal stones related to deficient activity of adenine phosphoribosyl transferase.,allopurinol is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; maize starch; purified talc; povidone; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.